DB:6A3A

Stock Analysis Report

Executive Summary

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer.

Rewards

Revenue is forecast to grow 73.7% per year

Risk Analysis

Earnings are forecast to decline by an average of -14.3% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

+ 1 more risk


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Autolus Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6A3A's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

11.8%

6A3A

-1.0%

DE Biotechs

1.7%

DE Market


1 Year Return

-60.7%

6A3A

6.2%

DE Biotechs

15.0%

DE Market

Return vs Industry: 6A3A underperformed the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: 6A3A underperformed the German Market which returned 15% over the past year.


Shareholder returns

6A3AIndustryMarket
7 Day11.8%-1.0%1.7%
30 Day-11.2%-2.3%0.8%
90 Day-8.7%7.8%3.7%
1 Year-60.7%-60.7%6.4%6.2%18.5%15.0%
3 Yearn/a49.0%47.3%17.1%6.9%
5 Yearn/a12.6%10.3%24.3%7.3%

Price Volatility Vs. Market

How volatile is Autolus Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Autolus Therapeutics undervalued compared to its fair value and its price relative to the market?

1.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6A3A's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6A3A's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6A3A is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 6A3A is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6A3A's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6A3A is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Autolus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-14.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6A3A is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6A3A is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6A3A is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6A3A's revenue (73.7% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 6A3A's revenue (73.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6A3A is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Autolus Therapeutics performed over the past 5 years?

-54.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6A3A is currently unprofitable.

Growing Profit Margin: 6A3A is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6A3A is unprofitable, and losses have increased over the past 5 years at a rate of -54.7% per year.

Accelerating Growth: Unable to compare 6A3A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6A3A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 6A3A has a negative Return on Equity (-47.57%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Autolus Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 6A3A's short term assets ($260.2M) exceed its short term liabilities ($20.6M).

Long Term Liabilities: 6A3A's short term assets ($260.2M) exceed its long term liabilities ($24.4M).


Debt to Equity History and Analysis

Debt Level: 6A3A is debt free.

Reducing Debt: 6A3A has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 6A3A has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 6A3A's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6A3A has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 6A3A has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -51.5% each year.


Next Steps

Dividend

What is Autolus Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 6A3A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6A3A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6A3A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6A3A's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6A3A's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Chris Itin (55yo)

3.9yrs

Tenure

US$1,239,300

Compensation

Dr. Christian Martin Itin, also known as Chris, Ph.D., has been the Chief Executive Officer of Autolus Therapeutics Plc. and Autolus Limited since March 3, 2016. Dr. Itin has been Director of Autolus Holdi ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD1.61M) is above average for companies of similar size in the German market ($USD801.26K).

Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Christian Itin
Chairman & CEO3.9yrsUS$1.24m2.04% $11.0m
Martin Pulé
Founder0yrsno data1.34% $7.2m
Andrew Oakley
CFO & Senior VP1.7yrsno datano data
Christopher Vann
Senior VP & COO3.3yrsno data0.21% $1.2m
Matthias Alder
Senior VP2.6yrsUS$372.20k0.24% $1.3m
Muhammad Al-Hajj
Senior Vice President of Translational Sciences2.6yrsno datano data
Vijay Peddareddigari
Senior VP & Chief Medical Officer3.9yrsno data0.087% $468.5k
Adam Hacker
Senior Vice President of Regulatory Affairs & Quality1.3yrsno datano data
Silvia Taylor
Vice President of Corporate Affairs & Communications0yrsno datano data
David Brochu
Senior VP & Head of Product Delivery0.3yrsno datano data

2.6yrs

Average Tenure

52yo

Average Age

Experienced Management: 6A3A's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christian Itin
Chairman & CEO3.9yrsUS$1.24m2.04% $11.0m
Martin Pulé
Founder0yrsno data1.34% $7.2m
Cynthia Butitta
Non-Executive Director1.7yrsUS$77.70kno data
John Berriman
Non-Executive Director1.7yrsUS$100.50k0.26% $1.4m
Martin Murphy
Non-Executive Director1.7yrsUS$22.10kno data
Joseph Anderson
Non-Executive Director1.7yrsUS$25.10kno data
Kapil Dhingra
Non-Executive Director1.7yrsUS$44.00k0.14% $758.3k
Linda Bain
Non-Executive Director1.7yrsUS$266.10kno data

1.7yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 6A3A's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.6%.


Top Shareholders

Company Information

Autolus Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Autolus Therapeutics plc
  • Ticker: 6A3A
  • Exchange: DB
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$583.958m
  • Listing Market Cap: US$538.584m
  • Shares outstanding: 52.23m
  • Website: https://www.autolus.com

Number of Employees


Location

  • Autolus Therapeutics plc
  • Forest House
  • 58 Wood Lane
  • London
  • Greater London
  • W12 7RZ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AUTLNasdaqGS (Nasdaq Global Select)YesSPON ADS EA REP 1 ORD SHSUSUSDJun 2018
6A3ADB (Deutsche Boerse AG)YesSPON ADS EA REP 1 ORD SHSDEEURJun 2018

Biography

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/16 22:43
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.